Physician

Alan Feldman, M.D.

According to 2025 Medicare claims, Alan Feldman, M.D. (NPI: 1427195114) practices endocrinology in the West Palm Beach-Boca Raton-Delray Beach, FL market, with the plurality of this provider's patient population coming from Palm Beach, FL. This provider's primary affiliated billing organization is ALEKSANDRA KRAEHER MD PA (NPI: 1497876973; TIN: 030530441) and primary practice location at 33458-4831. Feldman is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Feldman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,138 traditional Medicare patients, billed 3,467 HCPCS/CPT codes, and received $234,176 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 6,153 prescription claims across 902 beneficiaries totaling $2,953,011 in drug costs, led by Ozempic (Semaglutide). DME data shows 965 claims. Open Payments data shows 89 records totaling $2,165. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $155,188 to $234,176. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $860,671 to $2,953,011. For DME billing, reported payments moved sharply higher in recent years, from $3,169 to $292,358.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	615	2,469	$155,188
2016	748	2,639	$167,845
2017	776	2,820	$162,587
2018	811	2,991	$176,730
2019	859	3,155	$181,548
2020	874	2,877	$180,668
2021	933	3,129	$212,310
2022	1,029	3,354	$233,530
2023	1,049	3,299	$230,994
2024	1,138	3,467	$234,176

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	450	4,172	$860,671
2016	517	4,751	$1,262,858
2017	556	5,189	$1,588,632
2018	592	5,150	$1,984,663
2019	643	5,296	$2,098,601
2020	672	5,353	$2,473,692
2021	733	5,326	$2,714,712
2022	769	5,198	$2,607,244
2023	803	5,548	$3,078,064
2024	902	6,153	$2,953,011

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	226	529	$9,779
2016	231	522	$9,209
2017	230	514	$11,339
2018	270	710	$46,821
2019	308	842	$94,587
2020	311	1,136	$170,673
2021	257	1,127	$176,459
2022	301	1,307	$216,118
2023	289	1,423	$263,731
2024	269	965	$307,194

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	145	145	$121
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	1,046	2,025	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	32	32	$68
95251	Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report	187	501	$27
82947	Blood glucose (sugar) level	317	661	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	596	26,262	$831,814
Mounjaro	Tirzepatide	390	14,016	$504,164
Jardiance	Empagliflozin	348	24,436	$462,935
Trulicity	Dulaglutide	128	5,694	$190,505
Januvia	Sitagliptin Phosphate	79	5,370	$96,982

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	122	598	$256,286
J1817	Insulin for administration through dme (i.e., insulin pump) per 50 units	N	N/R	46	$14,965
A4224	Supplies for maintenance of insulin infusion catheter, per week	N	17	49	$14,392
E0784	External ambulatory infusion pump, insulin	Y	N/R	33	$11,264
A4225	Supplies for external insulin infusion pump, syringe type cartridge, sterile, each	N	17	50	$4,276

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	89	$2,165	Novo Nordisk Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alan Feldman, M.D.?

Tedicare shows public-source Medicare data for Alan Feldman, M.D. (NPI 1427195114), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alan Feldman, M.D. have ACO affiliation data?

Alan Feldman, M.D. is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Alan Feldman, M.D.?

Alan Feldman, M.D. is linked to ALEKSANDRA KRAEHER MD PA (billing NPI 1497876973) in the available physician profile data.

Does Alan Feldman, M.D. have Open Payments data?

Alan Feldman, M.D. has 89 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.